Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 22 publications
ENGOT-OV16/NOVA trial of niraparib in recurrent ovarian cancer: Survival and long-term safety.
Journal: Gynecologic oncology
Published: January 11, 2025
A personalized probabilistic approach to ovarian cancer diagnostics.
Journal: Gynecologic oncology
Published: August 15, 2023
Label-free microfluidic enrichment of cancer cells from non-cancer cells in ascites.
Journal: Scientific reports
Published: February 16, 2021
High throughput, label-free isolation of circulating tumor cell clusters in meshed microwells.
Journal: Nature communications
Published: November 23, 2020
Long-term safety in patients with recurrent ovarian cancer treated with niraparib versus placebo: Results from the phase III ENGOT-OV16/NOVA trial.
Journal: Gynecologic oncology
Published: July 14, 2020
Niraparib Maintenance Treatment Improves Time Without Symptoms or Toxicity (TWiST) Versus Routine Surveillance in Recurrent Ovarian Cancer: A TWiST Analysis of the ENGOT-OV16/NOVA Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 14, 2019
Niraparib Maintenance Therapy in Patients With Recurrent Ovarian Cancer After a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16/NOVA Trial.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: June 08, 2019
A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study.
Journal: Gynecologic oncology
Published: May 13, 2019
Machine learning predicts individual cancer patient responses to therapeutic drugs with high accuracy.
Journal: Scientific reports
Published: October 19, 2018
Quality of life in patients with recurrent ovarian cancer treated with niraparib versus placebo (ENGOT-OV16/NOVA): results from a double-blind, phase 3, randomised controlled trial.
Journal: The Lancet. Oncology
Published: January 30, 2018
Evidence for the importance of post-transcriptional regulatory changes in ovarian cancer progression and the contribution of miRNAs.
Journal: Scientific reports
Published: May 12, 2017
Last Updated: 09/26/2026